Proadm As Marker Indicating An Adverse Event

Abstract

The present invention relates to diagnosis, prognosis, risk assessment, and/or risk stratification of an adverse event, particularly mortality, of a subject. The invention relates to a method that comprises determining a level of proadrenomedullin (proADM) in a sample of said subject, and wherein said level of proADM is indicative of said adverse event of said subject, wherein said level of proADM is compared to a reference level of proADM; and wherein said adverse event of said subject is identified based on the comparison. The invention further relates to kits for carrying out the methods of the invention.


Claims

Download Citation


Sign in to the Lens

Feedback